Suprachoroidal Injection of CLS-TA Alone or With Aflibercept in Subjects With Diabetic Macular Edema

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 10, 2016

Primary Completion Date

October 17, 2017

Study Completion Date

October 17, 2017

Conditions

Diabetic Macular Edema

Interventions

DRUG

IVT Aflibercept

IVT aflibercept \[2 mg (50 µL)\]

DRUG

SC CLS-TA

\[4 mg (100 µL)\]

Trial Locations (2)

Retina Consultants of Houston, PA, The Woodlands

Retina Vitreous Associates Medical Group Inc, Mountain View